Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Cited by (1,000)

Items 201–300 of 1,000

1. Cold atmospheric plasma for addressing the COVID‐19 pandemic
   Zhitong Chen, Fan Bai, Steven John Jonas, Richard E. Wirz · 2022 · Plasma Processes and Polymers
2. Race, Ethnicity, and Health Disparities in US Children With COVID-19: A Review of the Evidence and Recommendations for the Future
   Claudia P Vicetti Miguel, Shom Dasgupta-Tsinikas, Gabriella S Lamb, Liset Olarte, Roberto P. Santos · 2022 · Journal of the Pediatric Infectious Diseases Society
3. Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study
   Nikolaus Kneidinger, Matthias Hecker, Vasiliki Bessa, Ina M. Hettich, Alexandra Wald, Sabine Wege, A. Nolde, Maike Oldigs, Zulfiya Syunyaeva, Heinrike Wilkens et al. · 2022 · Infection
4. The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19—Results from a pragmatic randomized clinical trial
   Ikram Din Ujjan, Saeed Khan, Roohi Nigar, Hammad Ahmed, Sagheer Ahmad, Amjad P. Khan · 2023 · Frontiers in Nutrition
5. Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients
   Timothée Bruel, Lou-Léna Vrignaud, Françoise Porrot, Isabelle Staropoli, Delphine Planas, Florence Guivel‐Benhassine, Julien Puech, Matthieu Prot, Sandie Munier, William Bolland et al. · 2023 · Med
6. Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science
   Michael S. Saag · 2022 · Physiological Reviews
7. Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study
   Dafna Yahav, Ruth Rahamimov, Tiki Mashraki, Naomi Ben-Dor, Tali Steinmetz, Timna Agur, Boris V. Zingerman, Michal Herman‐Edelstein, Shelly Lichtenberg, Haim Ben‐Zvi et al. · 2022 · Transplant International
8. Systemic sclerosis in the time of COVID-19
   Anna‐Maria Hoffmann‐Vold, Oliver Distler, Cosimo Bruni, Christopher Paul Denton, Jeska K de Vries-Bouwstra, Marco Matucci‐Cerinic, Madelon C Vonk, Armando Gabrielli · 2022 · The Lancet Rheumatology
9. Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop
   Eloise Williams, Kathrine J. Craig, Christopher Chiu, Hugh T Davies, Stephanie Ellis, Claudia Emerson, Euzebiusz Jamrozik, Monica L Jefford, Gagandeep Kang, Melissa C. Kapulu et al. · 2022 · Vaccine
10. Identification and Development of Therapeutics for COVID-19
    Halie M. Rando, Nils Wellhausen, Soumita Ghosh, Alexandra J. Lee, Anna Ada Dattoli, Fengling Hu, James Brian Byrd, Diane N. Rafizadeh, Ronan Lordan, Yanjun Qi et al. · 2021 · mSystems
11. Therapeutic role of immunomodulators during the COVID-19 pandemic– a narrative review
    Hebah Alhajeri, Fatemah Baron, Fatemah Abutiban, Muna Al Mutairi, Yasser Ali, Adel M. Al-Awadhi, Anwar Albasri, Ali Aldei, Ahmad Alenizi, Naser Alhadhood et al. · 2022 · Postgraduate Medicine
12. SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets
    Pooja Shivshankar, Harry Karmouty‐Quintana, Tingting Mills, Marie–Françoise Doursout, Yanyu Wang, Agnieszka K. Czopik, Scott E. Evans, Holger K. Eltzschig, Xiaoyi Yuan · 2022 · Inflammation
13. Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
    Raymund Rabe Razonable, Sidna M. Tulledge‐Scheitel, Sara N. Hanson, Richard F. Arndt, Leigh Lewis Speicher, Teresa A Seville, Jennifer J. Larsen, Ravindra Ganesh, John Charles O’Horo · 2022 · Open Forum Infectious Diseases
14. Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2
    Katherine U. Gaynor, Marina Vaysburd, Maximilian A. J. Harman, Anna Albecka, Philip D. Jeffrey, Paul Beswick, Guido Papa, Liuhong Chen, Donna L. Mallery, Brian McGuinness et al. · 2023 · Nature Communications
15. Independent Oversight of Clinical Trials through Data and Safety Monitoring Boards
    Scott R. Evans · 2022 · NEJM Evidence
16. Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19
    Emmanuel Lafont, Hélène Péré, David Lebeaux, Geoffrey Cheminet, Éric Thervet, R. Guillemain, Adrien Flahault · 2022 · Journal of Antimicrobial Chemotherapy
17. Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era
    Erin K McCreary, Kevin E. Kip, Kevin Collins, Tami E. Minnier, Graham M. Snyder, Ashley Steiner, Russell Meyers, Tina Borneman, Michelle Adam, Lauren Thurau et al. · 2022 · Open Forum Infectious Diseases
18. Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations
    Francesco Passamonti, Emanuele Nicastri, Alice Di Rocco, Attilio Guarini, Adalberto Ibatici, Stefano Luminari, Małgorzata Mikulska, Carlo Visco · 2022 · Hematological Oncology
19. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
    Fulvia Mazzaferri, Massimo Mirandola, Alessia Savoldi, Pasquale De Nardo, Matteo Morra, Maela Tebon, Maddalena Armellini, Giulia De Luca, Lucrezia Calandrino, Lolita Sasset et al. · 2022 · eLife
20. Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials
    Qinglin Cheng, Junfang Chen, Qingjun Jia, Zijian Fang, Gang Zhao · 2021 · Aging
21. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes
    Germaine Wong, Matthew Rowlandson, Dharshana Sabanayagam, Andrew N. Ginn, Kathy Kable, Frederika Sciberras, Eric Hoi Kit Au, Jenny L. Draper, Alicia Arnott, Vitali Sintchenko et al. · 2022 · Transplantation
22. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors
    Payton A. B. Weidenbacher, Eric Waltari, Izumi de los Rios Kobara, Benjamin N. Bell, Mary Kate Morris, Ya-Chen Cheng, Carl Veith Hanson, John E. Pak, Peter S. Kim · 2022 · Nature Chemical Biology
23. COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
    Michael A. Chary, Alexander F. Barbuto, Sudeh Izadmehr, Marc Tarsillo, Eduardo Fleischer, Michele M. Burns · 2023 · Journal of Medical Toxicology
24. Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
    Katie Harman, Sophie Nash, Harriet H. Webster, Natalie Groves, Jo L Hardstaff, Jessica R. E. Bridgen, Paula Bianca Blomquist, Russell Hope, Efejiro Ashano, Richard E. Myers et al. · 2023 · Influenza and Other Respiratory Viruses
25. A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity
    Leire de Campos‐Mata, Benjamin Trinité, Andrea Modrego, Sonia Tejedor Vaquero, Edwards Pradenas, Anna Pons-Grífols, Natalia Rodrigo Melero, Diego Carlero, Sílvia Marfil, César A. Santiago et al. · 2024 · Nature Communications
26. The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
    Lina Kamal, Ahmed Ramadan, Suha A. Farraj, Lydia Bahig, Sameera Ezzat · 2022 · Saudi Pharmaceutical Journal
27. A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
    Xiaofei Wang, Ao Hu, Xiangyu Chen, Yixin Zhang, Fei Yu, Shuai Yue, Arong Li, Junsong Zhang, Zhiwei Pan, Yang Yang et al. · 2022 · Signal Transduction and Targeted Therapy
28. Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial
    Leon Peto, Peter Horby, Martin Landray · 2022 · Advances in Biological Regulation
29. Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab
    Clara Luzia Magnus, Andreas Hiergeist, Philipp Schuster, Anette Rohrhofer, Jan Medenbach, André Gessner, David Peterhoff, Bárbara Schmidt · 2022 · Frontiers in Immunology
30. Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients
    Shin Takayama, Takao Namiki, Ryutaro Arita, Rie Ono, Akiko Kikuchi, Minoru Ohsawa, Natsumi Saito, Satoko Suzuki, Hajime Nakae, Seiichi Kobayashi et al. · 2022 · Frontiers in Pharmacology
31. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
    Gizem Kayki‐Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, Martin Christian Michel · 2022 · Naunyn-Schmiedeberg s Archives of Pharmacology
32. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
    Yun Ji, Qi Zhang, Lin Cheng, Jiwan Ge, Ruoke Wang, Mengqi Fang, Eric M. Mucker, Peng Chen, Ji Ma, Rui Zhang et al. · 2022 · Frontiers in Immunology
33. What is sotrovimab, the COVID drug the government has bought before being approved for use in Australia?
    Elise A. Schubert, Nial Wheate, Lifeng Kang · 2021
34. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir
    Santiago Moreno, Bernardino Alcázar-Navarrete, Carlos Dueñas, Juan González del Castillo, Julián Olalla, Antonio Antela · 2022 · Drug Design Development and Therapy
35. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants
    J. Andrew Duty, Thomas Kraus, Heyue Zhou, Yanliang Zhang, Namir Shaabani, Soner Yildiz, Na Du, Alok Singh, Lisa Miorin, Donghui Li et al. · 2022 · Med
36. Coagulopathy during COVID-19 infection: a brief review
    Robin M. Cunningham, Kyle L Johnson Moore, Jacen S. Moore · 2022 · Clinical and Experimental Medicine
37. An Overview of Repurposed Drugs for Potential COVID-19 Treatment
    Kamini Govender, Anil Amichund Chuturgoon · 2022 · Antibiotics
38. Intramuscular Versus Intravenous SARS-CoV-2 Neutralising Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomised Non-Inferiority Clinical Trial
    Adrienne E. Shapiro, Elias H. Sarkis, Jude Acloque, Almena Free, Yaneicy Gonzalez‐Rojas, Rubaba Hussain, Erick Juarez, Jaynier Moya, Naval Parikh, David Inman et al. · 2022 · Open Forum Infectious Diseases
39. Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study
    Adrian Matthew Shields, Sian Elizabeth Faustini, Harriet J. Hill, Saly Al‐Taei, Chloe Tanner, Fiona B. Ashford, Sarita Workman, Fernando Moreira, Nisha Verma, Hollie Wagg et al. · 2022 · Frontiers in Immunology
40. Beneficial and Harmful Effects of Monoclonal Antibodies for the Treatment and Prophylaxis of COVID-19: Systematic Review and Meta-Analysis
    Adrián Vladimir Hernández, Alejandro Piscoya, Vinay Pasupuleti, Mi T. Phan, Sreya Julakanti, Phirin Khen, Yuani M. Roman, César Omar Carranza-Tamayo, Angel Arturo Escobedo, C. Michael White · 2022 · The American Journal of Medicine
41. SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy
    Desh Deepak Singh, Anshul Sharma, Hae‐Jeung Lee, Dharmendra Kumar Yadav · 2022 · Frontiers in Cellular and Infection Microbiology
42. Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection
    Lorenza Romani, Francesca Ippolita Calò Carducci, Sara Chiurchiù, Laura Cursi, Maia De Luca, Martina Di Giuseppe, Andrzej Krzysztofiak, Laura Lancella, Paolo Palma, Leonardo Vallesi et al. · 2022 · Children
43. Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
    Alice Cho, Frauke Muecksch, Zijun Wang, Tarek Ben Tanfous, Justin DaSilva, Raphael Raspe, Brianna Johnson, Eva Bednarski, Víctor Ramos, Dennis J. Schaefer-Babajew et al. · 2022 · The Journal of Experimental Medicine
44. A comprehensive protein design protocol to identify resistance mutations and signatures of adaptation in pathogens
    Aditya Kumar Padhi, Timir Tripathi · 2022 · Briefings in Functional Genomics
45. Stable nebulization and muco‐trapping properties of regdanvimab/ IN ‐006 support its development as a potent, dose‐saving inhaled therapy for COVID ‐19
    Morgan D. McSweeney, Ian E. Stewart, Zach Richardson, Hyunah Kang, Yoona Park, Cheol-Min Kim, Karthik Tiruthani, Whitney Wolf, Alison Schaefer, Priya A. Kumar et al. · 2022 · Bioengineering & Translational Medicine
46. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
    Ahmed Zaqout, Muna Almaslamani, Hiam S. Chemaitelly, Samar A. Hashim, Ajithkumar Valooparambil Ittaman, Abeir Alimam, Fatma Rustom, Joanne Daghfal, Mohammed Abukhattab, Sawsan AlMukdad et al. · 2022 · International Journal of Infectious Diseases
47. Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2
    Simone Di Micco, Rahila Rahimova, Marina Sala, Maria Carmina Scala, Giovanni Vivenzio, Simona Musella, Graciela Andreï, Kim Remans, Léa Mammri, Robert Snoeck et al. · 2022 · European Journal of Medicinal Chemistry
48. Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients
    Surabhi B Vora, Janet A. Englund, Indi Trehan, Alpana Waghmare, Ada Kong, Amanda Adler, Danielle M. Zerr · 2022 · The Pediatric Infectious Disease Journal
49. Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial
    Leila N. Atmowihardjo, Job R. Schippers, Erik Duijvelaar, Imke Heleen Bartelink, Pierre M. Bet, Noortje Swart, Nienke van Rein, Keith Purdy, David Cavalla, Andrew B. McElroy et al. · 2023 · Critical Care
50. A study on the effect of natural products against the transmission of B.1.1.529 Omicron
    Samar Sami Alkafaas, Abanoub Mosaad Abdallah, Aya Misbah Hussien, Heba Bedair, Mahmoud Abdo, Soumya Bikash Ghosh, Sara Samy Elkafas, Wilgince Apollon, Morteza Saki, Samah A. Loutfy et al. · 2023 · Virology Journal
51. The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection
    Déborah Lécuyer, Roberta Nardacci, Désirée Tannous, Emie Gutierrez-Mateyron, Aurélia Deva Nathan, Frédéric Subra, Cristina Di Primio, Paola Quaranta, Vanessa Petit, Clémence Richetta et al. · 2023 · Frontiers in Immunology
52. First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants
    Allison Titong, Sachith Gallolu Kankanamalage, Jianbo Dong, Betty C. B. Huang, Nicholas Spadoni, Bo Wang, Meredith Wright, Keegan L. J. Pham, Anh Hai Le, Yue Liu · 2022 · Scientific Reports
53. Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases
    Carlos Martínez-Chinchilla, Lucía Vázquez-Montero, Natalia Palazón Carrión, Isabel Fernández-Román, José López-Barba, Luis de la Cruz‐Merino, Jesús Rodríguez‐Baño, Zaira Raquel Palacios-Baena · 2022 · Frontiers in Immunology
54. Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients
    Carlos Spuch, Marta López-García, Tania Rivera Baltanás, Jorge Julio Cabrera, Sudhir Gadh, Daniela Rodrígues-Amorím, Tania Álvarez-Estévez, Almudena Mora, Marta Iglesias‐Martínez‐Almeida, Luis Freiría‐Martínez et al. · 2022 · Frontiers in Pharmacology
55. Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
    Greta Santi Laurini, Nicola Montanaro, Domenico Motola · 2022 · Journal of Clinical Medicine
56. Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
    Yuanyuan Qiao, Jesse W. Wotring, Charles J. Zhang, Xia Jiang, Lanbo Xiao, Andy Watt, Danielle Gattis, Eli Scandalis, Susan M. Freier, Yang Zheng et al. · 2023 · PLoS ONE
57. Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management
    Jonathan Z. Li, Rajesh Tim Gandhi · 2022 · JAMA
58. The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials
    Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan · 2021 · Immunopharmacology and Immunotoxicology
59. Outpatient Therapies for COVID-19: How Do We Choose?
    Todd Campbell Lee, Andrew Mark Morris, Steven A. Grover, Srinivas Murthy, Emily Gibson McDonald · 2022 · Open Forum Infectious Diseases
60. SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
    Abigael Eva Chaouat, Hagit Achdout, Inbal Kol, Orit Berhani, Gil Roi, Einat B. Vitner, Sharon Melamed, Boaz Politi, Eran Zahavy, Ilija Brizić et al. · 2021 · PLoS Pathogens
61. Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies
    Sebastian Reinig, Shin‐Ru Shih · 2023 · Biomedical Journal
62. Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform
    Bang Zheng, John Tazare, Linda Nab, Amelia C. A. Green, Helen J Curtis, Viyaasan Mahalingasivam, Emily L. Herrett, Ruth E. Costello, Rosalind M. Eggo, Victoria Speed et al. · 2023 · The Lancet Regional Health - Europe
63. Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial
    Jin-ping Zheng, Yun Ling, Liang-shuang Jiang, Piroon Mootsikapun, Hongzhou Lu, Methee Chayakulkeeree, Lixiu Zhang, Pureepat Arttawejkul, Fengyu Hu, Thi Ngoc Lan Truong et al. · 2023 · Virology Journal
64. Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic
    David J. H. Bian, Siham Sabri, Bassam Abdulkarim · 2022 · Cancers
65. Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial
    Huijie Bian, Liang Chen, Zhaohui Zheng, Xiuxuan Sun, Jiejie Geng, Ruo Chen, Ke Wang, Xu Yang, Shirui Chen, Siyu Chen et al. · 2023 · Signal Transduction and Targeted Therapy
66. Delta-Omicron recombinant escapes therapeutic antibody neutralization
    Ralf Duerr, Hao Zhou, Takuya Tada, Dacia Dimartino, Christian Marier, Paul Zappile, Guiqing Wang, Jonathan Plitnick, Sara B. Griesemer, Roxie C. Girardin et al. · 2023 · iScience
67. Predisposing factors for admission to intensive care units of patients with COVID-19 infection—Results of the German nationwide inpatient sample
    Karsten Keller, Ioannis T. Farmakis, Luca Valerio, Sebastian Koelmel, Johannes Wild, Stefano Barco, Frank Patrick Schmidt, Christine Espinola–Klein, Stavros Konstantinides, Thomas F. Münzel et al. · 2023 · Frontiers in Public Health
68. SARS‐CoV‐2 vaccine antibody response and breakthrough infections in transplant recipients
    Benedict T. K. Vanlerberghe, Casper Vrij, Kris Bogaerts, Pieter Vermeersch, Katrien Lagrou, Geert Molenberghs, Filip Rega, Laurens Joseph Ceulemans, Dirk E. Van Raemdonck, Ina Jochmans et al. · 2023 · Journal of Medical Virology
69. Memory B cell development elicited by mRNA booster vaccinations in the elderly
    Zijun Wang, Frauke Muecksch, Raphael Raspe, Frederik Johannsen, Martina Turroja, Marie Canis, Mohamed A. ElTanbouly, Gabriela S. Silva Santos, Brianna Johnson, Viren A. Baharani et al. · 2023 · The Journal of Experimental Medicine
70. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review
    Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, Catherine Rolland, Louis Lavoie, Andrew Skingsley, Emily J. Lloyd · 2023 · Infection
71. Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology
    Daniel N. Streblow, Alec J. Hirsch, J. Stanton, Anne D. Lewis, L. Colgin, A. Hessell, C. Kreklywich, Jessica L. Smith, William F. Sutton, David Chauvin et al. · 2023 · Nature Communications
72. Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
    Lingyan Cui, Tingting Li, Wenhui Xue, Sibo Zhang, Hong Wang, Hongjing Liu, Ying Gu, Ningshao Xia, Shaowei Li · 2024 · Viruses
73. Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern
    Adonis A. Rubio, Viren A. Baharani, Bernadeta Dadonaite, Megan Parada, Morgan E. Abernathy, Zijun Wang, Yu Erica Lee, Michael R. Eso, Jennie L. Phung, Israel Ramos et al. · 2025 · Science Translational Medicine
74. Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study
    Vincenzo Scaglione, Salvatore Rotundo, Nadia Marascio, Carmela De Marco, Rosaria Lionello, Claudia Veneziano, Lavinia Berardelli, Angela Quirino, Vincenzo Olivadese, Francesca Serapide et al. · 2022 · BMC Infectious Diseases
75. Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort)
    Tommaso Manciulli, Michele Spinicci, Barbara Rossetti, Roberta Maria Antonello, Filippo Lagi, Anna Barbiero, Flavia Chechi, Giuseppe Formica, Emanuela Francalanci, Mirco Alesi et al. · 2023 · Viruses
76. Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
    Sean Wei Xiang Ong, Dongdong Ren, Pei Hua Lee, Stephanie Sutjipto, Christopher Dugan, Bo Yan Khoo, Jun Xin Tay, Shawn Sushilan Vasoo, Barnaby Edward Young, David Chien Lye · 2022 · Antibiotics
77. Trends in survival during the pandemic in patients with critical COVID-19 receiving mechanical ventilation with or without ECMO: analysis of the Japanese national registry data
    Shinichiro Ohshimo, Keibun Liu, Takayuki Ogura, Yoshiaki Iwashita, Shigeki Kushimoto, Nobuaki Shime, Satoru Hashimoto, Yuji Fujino, Shinhiro Takeda, on behalf of the Japan ECMO Network · 2022 · Critical Care
78. Investigation on the Essential Oils of the Achillea Species: From Chemical Analysis to the In Silico Uptake against SARS-CoV-2 Main Protease
    Hossein Rabbi Angourani, Armin Zarei, Maryam Manafi Moghadam, Ali Ramazani, Andrea Mastinu · 2023 · Life
79. Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals
    Tommaso Francesco Aiello, Pedro Puerta‐Alcalde, Mariana Chumbita, Carlos Lopera, Patricia Monzó, Albert Cortés‐Bullich, Francesc Fernández‐Avilés, María Suárez‐Lledó, Juan Gonzalo Correa, Valentín Ortiz‐Maldonado et al. · 2023 · Journal of Antimicrobial Chemotherapy
80. Clinical update on COVID-19 for the emergency and critical care clinician: Medical management
    Brit Long, Summer Chavez, Brandon M Carius, William J. Brady, Stephen Y. Liang, Alex Koyfman, Michael A. Gottlieb · 2022 · The American Journal of Emergency Medicine
81. The significance of advanced COVID-19 diagnostic testing in pandemic control measures
    Hang Fai Kwok · 2022 · International Journal of Biological Sciences
82. Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern
    Abigael Eva Chaouat, Ilija Brizić, Paola Kučan Brlić, Nofar Atari, Limor Kliker, Or Alfi, Michal Mandelboim, Dana G. Wolf, Laith Tafish, Inbal Kol et al. · 2022 · iScience
83. Conventional and Kampo Medicine Treatment for Mild-to-moderate COVID-19: A Multicenter, Retrospective, Observational Study by the Integrative Management in Japan for Epidemic Disease (IMJEDI Study-observation)
    Shin Takayama, Tetsuhiro Yoshino, Sayaka Koizumi, Yasuhito Irie, Tomoko Suzuki, Susumu Fujii, Rie Katori, Mosaburo Kainuma, Seiichi Kobayashi, Tatsuya Nogami et al. · 2022 · Internal Medicine
84. Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
    Lucy B M Cook, Gillian O'Dell, Eleni Vourvou, Renuka Palanicawandar, Sasha Marks, Dragana Milojković, Jane F. Apperley, Sandra Loaiza, Simone Claudiani, Marco Bua et al. · 2022 · Nature Communications
85. The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
    Aline Almeida-Oliveira, Diana Praia Borges Freire, Ana Rodrigues de Andrade, Amanda de Miranda Marques, Luciana da Silva Madeira, Jose Procopio Moreno Senna, Ivna Alana Freitas Brasileiro da Silveira, Beatriz de Castro Fialho · 2023 · Journal of Pharmaceutical Innovation
86. Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants
    Mellissa C. Alcantara, Yusuke Higuchi, Yuhei Kirita, Satoaki Matoba, Atsushi Hoshino · 2023 · Vaccines
87. Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
    Lena Jaki, Sebastian Weigang, Lisa Kern, Stefanie Kramme, Antoni G. Wrobel, Andrea Busse Grawitz, Philipp Nawrath, Stephen R. Martin, Theo Dähne, Julius Beer et al. · 2023 · Nature Communications
88. Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization
    Scott A. McConnell, Jaiprasath Sachithanandham, Nathan J. Mudrak, Xianming Zhu, Parsa Alba Farhang, Radamés J. B. Cordero, Maggie P. Wear, Janna R. Shapiro, Han-Sol Park, Sabra L. Klein et al. · 2023 · Cell chemical biology
89. Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial
    Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Juarez, M. Crespo Casal, Jaynier Moya, Diego R. Falci, Elias H. Sarkis, Joel Solis, Hanzhe Zheng, Nicola E. Scott et al. · 2021 · medRxiv
90. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
    David Totschnig, Max Augustin, Iulia Niculescu, Hermann Laferl, Sonja Jansen‐Skoupy, Clara Lehmann, Christoph Wenisch, Alexander Zoufaly · 2022 · Viruses
91. Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario
    Carolin Krekeler, Lea Elisabeth Reitnauer, Ulrike Bacher, Cyrus Khandanpour, Leander Steger, Göran Ramin Boeckel, Justine Klosner, Phil‐Robin Tepasse, Marcel Kemper, Marc Tim Hennies et al. · 2022 · Cancers
92. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
    Zhiyang Ling, Chunyan Yi, Xiaoyu Sun, Zhuo Yang, Bing Sun · 2022 · Science China Life Sciences
93. Technology-enabled virtual ward for COVID management of the elderly and immunocompromised in Singapore: a descriptive cohort
    Stephanie Q Ko, Shoban Krishna Kumar, Jonathan Edward Jacob, Benjamin Ming-Yew Hooi, Michelle Rui Ting Soo, Norshima Binte Nashi, Maria Teresa D. Cruz, Yeo Ai Wah, Wong Zhi Xin, Nares Smitasin et al. · 2023 · BMC Infectious Diseases
94. Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization
    Jing Yang, Sheng Lin, Zimin Chen, Fanli Yang, Liyan Guo, Lingling Wang, Yanping Duan, Xindan Zhang, Yushan Dai, Keqing Yin et al. · 2023 · PLoS Pathogens
95. Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency
    Bibi Uhre Nielsen, Camilla Heldbjerg Drabe, Mike Bogetofte Barnkob, Işık Somuncu Johansen, Anne Kirstine Kronborg Hansen, Anna Christine Nilsson, Line Dahlerup Rasmussen · 2022 · Frontiers in Immunology
96. Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic
    Giulia Garzi, Francesco Cinetto, Davide Firinu, Giulia Di Napoli, Gianluca Lagnese, Alessandra Punziano, Patrick Bez, Bianca Laura Cinicola, Giulia Anna Maria Luigia Costanzo, Riccardo Scarpa et al. · 2022 · Frontiers in Immunology
97. Comparative effectiveness of Paxlovid versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients: observational cohort study using the OpenSAFELY platform
    Bang Zheng, John Tazare, Linda Nab, Amir Mehrkar, Brian MacKenna, Ben M. Goldacre, Ian Douglas, Laurie A. Tomlinson · 2023 · medRxiv
98. Community-acquired bacterial coinfections and COVID-19
    Michael John Patton, Amit Gaggar, Matthew Might, Nathaniel B. Erdmann, Carlos Javier Orihuela, Kevin S. Harrod · 2023 · Physiological Reviews
99. Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series
    Guillaume Fernandes, Arnaud Devresse, Anaïs Scohy, Julien De Greef, Jean Cyr Yombi, Leïla Belkhir, Tom Darius, Michel Mourad, Antoine Buemi, Benoît Kabamba et al. · 2022 · Kidney Medicine
100. Druggable targets and therapeutic development for COVID-19
     Xiaohua Duan, Lauretta A. Lacko, Shuibing Chen · 2022 · Frontiers in Chemistry